Optimal Timing for Cessation of GLP-1 Agonist Before Elective Total Hip and Knee Arthroplasty

Shivan N Chokshi, Nuanqiu Hou, Marcus Christopher Ford, John R Crockarell¹, James L Guyton, William Michael Mihalko, Christopher T Holland

¹Campbell Clinic

INTRODUCTION:

Glucagon-like peptide-1 receptor agonists (GLP-1A) have advanced the treatment of type 2 diabetes and obesity. Given the prevalence of these conditions among candidates for total joint arthroplasty (TJA), managing GLP-1A in the perioperative period is crucial to minimize complications.

METHODS:

The TriNetX Research Network was queried for patients who underwent total hip or knee arthroplasty from January 2018 to January 2023. A control group of 206,005 patients with no prior Ozempic use was identified. Ozempic users were categorized based on when they stopped the medication before surgery: 30 days (482 patients), 14 days (591), 7 days (680), 5 days (758), 3 days (777), 1 day (706), and continued use through surgery (170). Propensity-matched cohorts were analyzed to determine the relationship between the time of last Ozempic dose and anesthesia complications using multivariate logistic regression.

RESULTS:

Stopping Ozempic 5 days before surgery was an independent risk factor for delayed emergence from anesthesia (OR 1.59, P=0.005); stopping 3 days (OR 1.84, P<0.001) and 1 day prior (OR 2.23, P<0.001) also increased this risk. For aspiration, stopping 7 days prior was a risk factor (OR 1.24, P=0.002), with higher risks for stopping 5 days (OR 2.53, P<0.001), 3 days (OR 3.09, P<0.001), and 1 day (OR 4.96, P<0.001) prior. Stopping 7 days before surgery also increased the risk for aspiration pneumonitis (OR 1.29, P<0.001), with even higher risks for stopping 5 days (OR 2.74, P<0.001) and 1 day prior (OR 2.74, P<0.001). Multivariate logistic regression identified last Ozempic dose at 7 days prior to surgery as an independent risk factor for conversion to intubation (OR 1.39 [95% CI 1.06-1.56], P=0.0343). Similarly, last Ozempic dose at 5 days (OR 2.09, [95% CI 1.76-2.36], P<0.001), 3 days (OR 4.68, [95% CI 4.40-4.97], P<0.001), and 1 day (OR 6.37, [95% CI 5.92-6.72], P<0.001) were independent risk factors for conversion to intubation. The highest risk for all complications was observed in patients who continued Ozempic use through surgery. Diabetes itself was not an independent risk factor for any of the complications.

DISCUSSION AND CONCLUSION:

Stopping Ozempic more than 7 days prior to surgery reduced the risk of delayed emergence from anesthesia and aspiration pneumonitis, additionally stopping 14 days prior to surgery reduced the risk of aspiration and conversion to intubation in this cohort. To minimize risks of delayed emergence from anesthesia, aspiration, aspiration pneumonitis, and conversion to intubation, ceasing GLP-1A 14 days before surgery is optimal. Careful planning and coordination in managing GLP-1A in the preoperative period are essential to optimize surgical outcomes

	OR'	95% CI	P-value
90 days	1.03	0.84-1.18	0.4906
14 days	1.06	0.95-1.22	0.1673
7 days	1.11	0.97-1.31	0.0977
5 days	1.59	1.34-1.82	0.005*
3 days	1.84	1.63-2.19	*D0000*
1 day	2.23	1.82-2.49	<0.0001*
Nesc	2.73	2.44-3.23	*0.000*
Rationau group: non-O.	mangic sease	history. OR-odds satis. C	roosfidesor inten
Table 2. Multivaria	te Analysis for Aspira		
	OR*	95% CI	P-value
90 days	1.02	0.96-1.23	0.2952
14 days	1.09	0.92-1.26	0.0981
7 days	1.24	1.07-1.40	0.002*
5 days	2.53	2.21-3.08	<0.000*
3 days	3.09	2.77-3.41	<0.000*
		4.53-5.29	<0.001*
Gaso One Controlled for age,		4.81-5.29 histop: Oll-rodds setin. C	<0.000*
Fanc One Controlled for age, Reference group: com-O	ser, mor, and past mobinal	history. Offi-rodds satis. C	
Fanc One Controlled for age, Reference group: com-O	sec, mor, and past mobinal comple users	history. Offi-rodds satis. C	
Nose Controlled for age. Technology group: non-th-	sec, noz, and past modical comple users to Amalysis far Aspira	histop. Off-odds sale. C	r-confidence (atten
Note Controlled for age, Todorner group: one-O: Table 3. Multivariat 30 days.	ses, nor, and past mobini comple atom for Analysis far Aspira OR*	history. Olf-rodds main. C dies Procurecedds 95% CI	-confidence inter-
None Note Controlled for age, Endwarer group: non-Or Table 3. Multivariar 90 days. 14 days	ces, mor, and past modical comple overs to Analysis far Aspira OR* 0.99	bissoy. Olivodo mis. C fina Paramonido 59% CI 0.77-1.31	P. value
Table 3. Multivaria 10 days 14 days 2 days	ors, nor, and past mobinil comple uses to Analysis for Aspira OR* 0.99 1.04	tine Parameetik 55% CI 0.77-1.31 0.88-1.34	P. value 0.6324 0.2347
None Note Controlled for age, Endwarer group: non-Or Table 3. Multivariar 90 days. 14 days	on, nor, and past mobinii compic uses to Analysis for Aspleta OR* 0.99 1.04 1.12	tion Parameetik 59% CI 0.77-1.31 0.89-1.34 0.87-1.29	P. value 0.63247 0.2347
None Controlled for age, Enformer group: non-O. Tablie 3. Multivariat 90 days 14 days 2 days 5 days 6 d	on, nor, and past mobinil comple seem OR* 0.99 1.04 1.12 1.29	tion Parameetite 595 CI 0.77-1.31 0.88-1.34 0.87-1.29 1.00-1.49	P. value 0.5324 0.2347 0.001*
Gene Controlled for age, Reference groups can-Os Fabile 3. Multibrarian 10 days 4	ocs, not, and past modical comple uses OR* 0.99 1.04 1.12 1.29 1.46	tion Procureceitic 55% C1 0.77-1.31 0.88-1.34 0.83-1.29 1.03-1.49 1.23-1.67	P. value 0.6324 0.2347 0.000* <0.000*
Some Jose Controlled for age, Reference gamps non-Os Fabrile 3. Multithraviae 40 days 4 da	rec, not, and past models comple seem to Analysis for Aspira GR* 0.99 1.04 1.12 1.29 1.46 2.74 2.82 zer, not, and past models or not, not, and past models or not	tion Paramonida 59% CI 0.77-1.31 0.89-1.34 0.83-1.29 1.00-1.49 1.23-1.67 2.38-3.05	P. value 0.8324 0.2947 0.000* -0.000* -0.000*
tone Controlled for age, to forbrane gamps non-Os abble 3. Multibrarian O days	rec, not, and past models comple seem to Analysis for Aspira GR* 0.99 1.04 1.12 1.29 1.46 2.74 2.82 zer, not, and past models or not, not, and past models or not	fina Paramonistis 59% CI 0.77-1.31 0.89-1.34 0.87-1.29 1.00-1.49 1.20-1.49 2.218-3.05 2.40-3.11	P. value 0.8324 0.2947 0.000* -0.000* -0.000*
Some Jose Controlled for age, Reference gamps non-Os Fabrile 3. Multithraviae 40 days 4 da	rec, not, and past models comple seem to Analysis for Aspira GR* 0.99 1.04 1.12 1.29 1.46 2.74 2.82 zer, not, and past models or not, not, and past models or not	fina Paramonistis 59% CI 0.77-1.31 0.89-1.34 0.87-1.29 1.00-1.49 1.20-1.49 2.218-3.05 2.40-3.11	P. value 0.8324 0.2947 0.000* -0.000* -0.000*
None Controlled for age, Pindramer group: non-Os Trable 3. Multivariat 90 days 6 days 5 days 5 days 6 days 8 days 1 d	rec, not, and past models comple seem to Analysis for Aspira GR* 0.99 1.04 1.12 1.29 1.46 2.74 2.82 zer, not, and past models or not, not, and past models or not	fina Paramonistis 59% CI 0.77-1.31 0.89-1.34 0.87-1.29 1.00-1.49 1.20-1.49 2.218-3.05 2.40-3.11	P. value 0.8324 0.2947 0.000* -0.000* -0.000*
Some Jose Controlled for age, Reference gamps non-Os Fabrile 3. Multithraviae 40 days 4 da	rec, not, and past models comple seem to Analysis for Aspira GR* 0.99 1.04 1.12 1.29 1.46 2.74 2.82 zer, not, and past models or not, not, and past models or not	fina Paramonistis 59% CI 0.77-1.31 0.89-1.34 0.87-1.29 1.00-1.49 1.20-1.49 2.218-3.05 2.40-3.11	P. value 0.8324 0.2947 0.000* -0.000* -0.000*
Associated for age, Edward groups and O. Edward groups and O. Edward groups and O. Edward age 4 days 4 d	ice, noc, and part modical comple sees for Analysis far Asplira GP 1,009 1,006 1,12 1,29 1,36 2,24 2,24 2,50, noc, and part modical comple sees	fina Paramonistis 59% CI 0.77-1.31 0.89-1.34 0.87-1.29 1.00-1.49 1.20-1.49 2.218-3.05 2.40-3.11	P. value 9.524 9.377 -0.009 -0.009 -0.009 -0.009 -0.009
Gross one Controlled for age, the Controlled for age, the Controlled for age, the Controlled for age, the Controlled for age, always al	sec, noc, and past modulal comple sum on Annalysis fair Asplina OR* 0.99 1.04 1.12 1.29 2.74 2.74 2.85 sec, noc, and past modulal comple sum Multivariate Analysis OR*	histop, Olf-odd min. C 59% CI 627-131 638-1,34 638-1,29 100-149 121-147 238-365 248-381 histop, Olf-odd min. C 59% CI	P-value 0.6324 0.2347 0.000* -0.000* -0.000* -0.000* -0.000*
Nace Visco Controlled for age, one-Ox Firsterner green, one-Ox Firstern	sec, noc, and past mobinil comple seen OR* OP* 1.09 1.10 1.20 2.20 2.00 2.00 Soc, noc, not past mobinil comple seen Multibariste Analysis OR* 1.12 1.10	histop, Olf-odds min. C 59% CI 0.77-1.31 0.89-1.34 0.87-1.29 1.00-1.49 1.20-1.49 2.28-3.07 2.49-5.11 histop, Olf-odds min. C 59% CI 0.87-1.31	P. value 0.524 0.2047 0.000* -0.000* -0.000* -0.000* -0.000* -0.000* -0.000* -0.000*
None Controlled for age, None Controlled for age, Disference games cone O. Table 3. Mathburshad 200 days 1d days 1	sec, nor, and past molisal comple seen GR* 0.09 1.12 1.29 1.46 2.74 2.74 2.80 sec, nor, and past molisal comple seen Madificardate Awalysis OR* 1.02 1.02 1.02 1.02 1.02 1.03	history, Oli-rodo min. C 55% CI 577-1-31 677-1-32 678-1-34 638-1-34 638-1-34 638-1-34 120-1-49 121-1-47 238-3-65 249-3-11 history, Oli-rodo min. C 50r Conversion to Int. 55% CI 638-1-31 638-1-31 638-1-31	P. value 0.524 0.397 0.000* 0.000* 0.000* 0.000* 0.000*
None None Controlled for age, Table 3, Multivarian Table 3, Multivarian 20 days 16 days 3 days 4 days 5 days 5 days 5 days 7 days 6 days 1 days	sec, noc, and past molical comple seem for Analysis for Aspira OR* 0.99 1.04 1.12 1.29 2.25 sec, noc, and past molical comple seem Madificariate Analysis 1.02 1.02 1.03 1.02 1.03 1.03	history, Oll-rodo sein. C fine Parametellic 95% CI 625-1-131 635-1-120 130-1-149 140-1-149 140-1-149 140-1-149 140-1-149 140-1-149 140-1-149 140-1-149 140-1-149 140-1	P. value 0.8224 0.2547 0.0079 -0.000*
Name None Controlled for age, Distribution groups one O. Table 3. Mathbracka 20 days 1d days 2d days days days days Supplementary Su	sec, nor, and past modeled some jet was a maleysis for Aspirar for	history, Oll-rodo seles, Cl. files Paramodelle \$555, Cl. -27-1,21 -28-1,29 -120-1,49 -121-1,47 -23-1,38 -2.43-3,11 history, Oll-rodo seles, C. -555, Cl. -	P. value 0.6324 0.2347 0.6079 <-0.000* <-0.000* -0.000* 0.00
Name None Controlled for age, Distribution groups one O. Table 3. Mathbracka 20 days 1d days 2d days days days days Supplementary Su	sec, nor, and past models on past models of Analysis for	history, Oll-rodo sein. C fine Parametellic 95% CI 625-1-131 635-1-120 130-1-149 140-1-149 140-1-149 140-1-149 140-1-149 140-1-149 140-1-149 140-1-149 140-1-149 140-1	P. value 0.8224 0.2547 0.0079 -0.000*
Nace Visco Controlled for age, one-Ox Firsterner green, one-Ox Firstern	sec, nor, and past modeled some jet was a maleysis for Aspirar for	history, Oll-rodo seles, Cl. files Paramodelle \$555, Cl. -27-1,21 -28-1,29 -120-1,49 -121-1,47 -23-1,38 -2.43-3,11 history, Oll-rodo seles, C. -555, Cl. -	P. value 0.6324 0.2347 0.6079 <-0.000* <-0.000* -0.000* 0.00